BioSpace News Archive

Ionis Pharmaceuticals, Inc. announced that the company has been notified by its partner Bayer about the decision to advance IONIS-FXI-LRx following positive clinical results.

The Board of AdAlta Limited, is pleased to announce the appointment of experienced global pharmaceutical executive Dr Tim Oldham as Chief Executive Officer and Managing Director.

Sage Therapeutics announced it will host a live webcast on Tuesday, November 12, 2019 at 8:00 a.m. EST to report its third quarter 2019 financial results and discuss recent business updates.

Ophthalmologist Jorn S. Jorgensen, CEO and Founder of EuroEyes, Implanted EVO ICLs in His Son, Jannik Jorgensen

BlueBee, a global bioinformatics solutions provider, has extended data operations to mainland China to serve genomic data processing needs in compliance with The Chinese Ministry of Health and Technology.

Boehringer Ingelheim announced today that in the Phase III INBUILD® trial nintedanib slowed lung function decline by 57% across the overall study population, as assessed by the annual rate of decline in forced vital capacity (FVC)i over 52 weeks in patients with chronic fibrosing interstitial lung disease (ILDs) with signs of progression

ImmunoMolecular Therapeutics (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, today announced that it has raised $10 million in Series A financing to advance its novel HLA-targeted discovery platform and develop its lead drug candidate in type 1 diabetes (T1D).

Physician practices struggling to comply with state government restrictions on opioid prescriptions now have an easy means of satisfying the requirements designed to prevent overdoses and drug misuse.

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it will be presenting at the inaugural MicroCap Rodeo Investor Conference in Austin, Texas on Tuesday, October 15 at 9:10 a.m. CDT.

Galderma, a global leader in skin health focused on developing innovative aesthetic solutions, recently announced the Phase 2 clinical trial results for its novel ready-to-use investigational botulinum toxin, QM1114